Eva Pharma manufactures and distributes pharmaceuticals at scale - roughly a million packs daily across more than 60 countries, with a footprint concentrated in the Middle East and Africa. The portfolio runs to over 300 products spanning oncology, neuroscience, respiratory health, and diabetes. That kind of operational surface area - three internationally certified manufacturing sites, two research centers, and a workforce north of 5,000 - means the attack profile is wide and the consequences of compromise are clinical, not just financial.
For a security team, the threat model here is shaped by pharmaceutical manufacturing and healthcare supply chain realities: protecting proprietary research data, safeguarding patient information across regulatory regimes that vary by jurisdiction, and ensuring operational technology on production lines stays uncompromised. The company's focus on low- to middle-income countries adds another layer - infrastructure constraints and regional threat actor activity both factor into how defenses get designed and deployed.
Eva Pharma's technical domains center on pharmaceutical manufacturing systems and healthcare research platforms. Security roles in this environment would involve securing industrial control systems that run production, managing identity and access across a large global workforce, and maintaining compliance across a patchwork of regional and international pharmaceutical regulations. The stakes are literal: uptime and integrity directly affect drug supply for patients in markets where alternatives may be scarce.
